Current research opportunities

Currently we have multiple recruiting portfolio studies within TEWV. The studies are categorised under the five corresponding areas for research;

  • Mental health services for older people (MHSOP)
  • Adult mental health (AMH)
  • Children and young people
  • Learning disabilities
  • Forensic mental health

For studies that are now completing follow up visits, and that are no longer recruiting, please refer to the Studies in follow up information below.

Mental health services for older people (MHSOP)

The MK-4305 study (The sleep study): This interesting clinical trial, sponsored by Merck, and in partnership with South Tees NHS Foundation Trust will assess the impact of a new medical treatment for those living with both Alzheimer’s disease and insomnia. The main criteria for eligible participants includes a diagnosis of mild to moderate Alzheimer’s disease and insomnia and are aged between 50 and 90. Participants will be involved in the study for nine weeks, including a three week screening period for eligibility, a four week treatment period and two weeks of post treatment follow-up, and must have a study partner who will support and accompany them to appointments. Anyone chosen to take part will wear a watch-like device for the duration of the study, which will monitor their activity and sleep. Information from the device will be uploaded to a tablet and will be assessed by the study team. The study is open to anyone from across the Trust area and will include appointments at Roseberry Park, Middlesbrough, as well as three overnight stays in the sleep laboratory at James Cook Hospital in Middlesbrough. If you are interested in taking part or finding out more please email .

CYGNUS: To support current healthcare decisions, there is a need to understand the impact of diagnosis and subsequent outcomes for patients with memory problems and those who care for them in real-world settings. The data, gathered over a year, will help to assess the value of interventions, evaluate data collection methods, and follow post-diagnosis progression of conditions. Close family or friends of CYGNUS study participants to be ‘study partners’, and we will collect a sample of data from them over the same time period. The Cygnus project will establish a digital healthcare platform with 3 aims: 1) To collect standardised data from two groups: (a) patients with cognitive impairment referred to memory assessment services, and (b) their supportive partners or caregivers, 2) Post-diagnosis collection of data about outcomes and episodes of care and, 3) To provide a well-characterised population who have consented to contact about future evaluation of technologies and interventions that might benefit patients and carers. For more information please contact 

AD GENETICS (Early and Late): AD Genetics is a National study run by Cardiff University. Since 2004 they have been collecting blood samples and interviewing people to try and understand more about how certain genes affect the likelihood of developing Alzheimer’s disease. So far over 3000 people have helped with the research and as a result they have been successful in finding many previously unknown genes that are involved in Alzheimer’s disease. We are recruiting individuals with Alzheimer’s Disease to search for environmental, biological and genetic factors that influence the progression of Alzheimer’s disease and other neurodegenerative disorders. For more information please contact

Journeying Through Dementia: The Journeying through Dementia Research study is based on the idea that what we do in our everyday lives is important for our general health and wellbeing. We want to find out whether attending the Journeying through Dementia programme can help people with early stage dementia to live a healthy and fulfilling life. This study opened to recruitment in late December 2016 and is hoping to recruit from York & Selby and Harrogate area. Our aim is to recruit 50 participants (25 for each area), these participants will be randomly allocated to either usual care or a tailored 12 week programme supported by a trained interventionist. For more information please contact

DECIDE: The number of people living in the UK with dementia is rising. Friends and family provide much of the care needed. Having a caring role may compromise well-being, quality of life (QoL), and finances. The annual cost of supporting people with dementia is estimated at £26.3 billion, with almost half being attributed to the care provided by 'informal carers'. Maintaining carer QoL and finding a way of measuring it are important not only for the carers and those cared for, but also for society. The aim of DECIDE is to develop a new reliable and valid measure that draws inductively on a range of constructs related to QoL of carers of people with dementia. The measure needs to be short enough to be used in research, in routine health, social and third sector care. For more information please contact

Adult mental health


Scene research study aims to improve quality of life and health outcomes for people with psychosis through a new structured intervention for expanding social networks.  Looking to survey 100 people aged between 18-65 years old with a diagnosis of psychosis-related condition (ICD-10 F20-29) and receiving care from outpatient secondary mental health services. We need clinicians to refer interested potential participants.  You can find out more at and contact to speak to our research staff working on the study, quoting ‘Scene’!

PIPP2 (Prevalence of Pathogenic Autoantibodies in Psychosis): open to patients aged 18-70 years with psychosis (exclusions are pre-existing major neurological disorder and primary drug-induced psychosis). The immune system normally controls our ability to fight infection. If the immune system goes wrong it may cause diseases called ‘autoimmune’ diseases. We can diagnose some of these autoimmune diseases using blood tests. We are specifically interested in antibodies affecting the N-methyl D-aspartate receptors (NMDA-r) or other neuronal membrane targets that may be the cause symptoms of psychosis and possibly cause some cases of schizophrenia. We are working with Early Intervention in Psychosis (EIP) services across England to estimate the prevalence of these autoimmune diseases in people with first episode psychosis. This study is quick, easy and actually very clinically-useful to busy clinicians who would like to exclude a potential underlying cause of psychosis in their patients (the tests would normally come at a significant cost to the Trust). For more information see the SINAPPS group studies website or contact

LQD - Lithium versus Quetiapine augmentation in Treatment resistant depression:  LQD aims to measure the effect of these treatments on your mood over 12 months and also the time until you finish taking the study medication.  LQD is a randomised controlled trial, designed to provide evidence of the effect of two therapies which are commonly added onto antidepressants for people with treatment resistant depression (i.e. depression where two or more different antidepressants have been tried but were unsuccessful). The main inclusion criteria are: Aged 18 or over, currently depressed, have tried two or more antidepressants in your current depressive episode but have not fully recovered with these and are currently taking an anti-depressant. For more information, please contact

Lifestyle Health and Wellbeing Survey:The health inequalities experienced by individuals with a serious mental illness (SMI) is well documented. These inequalities are partly attributable to modifiable factors, including those related to health behaviours. Lead by the University of York, this study involves service users with an SMI, such as psychosis or bipolar disorder, completing a 10 minute questionnaire focusing on health behaviours and motivation to change. With their consent, these service users become part of a cohort for a larger body of research looking at the physical health of people with an SMI. For more information please contact

Quality and Effectiveness of Supported Tenancies (QuEST):Around 60,000 people with mental health problems live in supported accommodation in England, costing the NHS and Local Authorities millions of pounds. However, little is known about the quality and effectiveness of supported accommodation services. This five year programme of research will address this evidence gap through four related projects. 1) adapt an existing quality assessment tool (the Quality Indicator for Rehabilitative Care - QuIRC) for supported accommodation services, 2) survey a nationally representative sample of supported accommodation services with the amended QuIRC, 3) interview service users and staff to identify the aspects of care they consider most useful and the challenges in providing them and 4) by investigating the feasibility of a large scale trial to compare the effectiveness of two commonly used models of supported accommodation: the “Train and Place” approach, that provides a constant level of staff on-site to a number of flats with the expectation of service users moving-on as they gain independent living skills; and the “Place and Train” approach, that provides floating outreach support of flexible intensity to service users living in a permanent, independent tenancy. For more information please contact

Adulthood Autism: This study aims to ask individuals with an autism diagnosis, and their carers/ relatives to share their experiences with the view to informing future service. This is achieved through completion of an in-depth questionnaire looking at issues such as: physical and mental health, employment, education, relationships, and support needs. This is a longitudinal cohort study meaning that service users are invited to respond to follow-up surveys which chart their changing needs over several years.For more information please contact

Effectiveness and cost-effectiveness of Mother and Baby Units vs Psychiatric Inpatient wards (ESMI):The Royal College of Psychiatrists state that women needing psychiatric admission post-delivery should be admitted to Mother and Baby Units (MBUs). MBUs aim not only to care for the mother's psychiatric needs but also to support themother and baby relationship, which may be at risk in this group. The study We will conduct a quasi experimental cohort study of women with acute severe mental disorders who need intensive treatment urgently following birth. This study aims to investigate the effectiveness and cost effectiveness of MBUs compared with general psychiatric wards or care from CRTs for acute severe postnatal disorders. For more information please contact

Genetic Case Control and Brain Imaging Studies of Mental Illness (DPIM):This study is trying to find more about the genetic causes of Schizophrenia, Bipolar Disorder and Alcohol dependence. You will be asked to engage in a short interview and have a blood sample taken. In a small number of cases a saliva sample may also be required.If you have any of these conditions and would like to take part please contact Sue Bonner on

Prevalance of Neuronal cell surface antibodies in Patients with Psychotic illness (PPiP - extension):The study wishes to establish the prevalence of these antibodies in a larger cohort of patients at first presentation of psychosis. This will involve taking an extra tube of blood at the same time as normal clinical blood testing. We wish to establish whether there are other, more sensitive markers of antibody activity in the serum of patients with psychosis. This will involve taking a larger quantity of blood from some patients. In those patients who are being treated with plasma exchange for their antibody disorder we wish to collect the discarded plasma for further investigation of immune markers. In this way we will establish   the prevalence and nature of this disorder. For more information, please contact

Evaluate the clinical and cost effectiveness of Relatives Education And Coping Toolkit (REACT):REACT is an online toolkit that provides relatives with the information and support they need. The toolkit has been adapted in light of feedback and will be delivered in an online trial to test its clinical and cost effectiveness across the UK. Relatives will be directed to the study website through a wide range of routes including clinical services, voluntary sector organisations, and web searches. The study team plan to recruit 666 relatives who will be allocated at random to either receive access to the REACT website, or to an online Resource Directory which includes information about all currently available services. They will be asked to complete questionnaires to assess their distress levels and wellbeing at the beginning, and after 12 and 24 weeks. For more information, please contact

European Long-acting Antipsychotics in Schizophrenia Trial (EULAST):The primary objective of the trial is to compare all cause discontinuation rates in patients with schizophrenia randomized to either one of the two depot medications (aripiprazole depot or paliperidone palmitate) with patients randomized to either one of the two oral formulations of the same medication (aripiprazole or paliperidone) over an 18 month follow-up period. For more information, please contact

Children and young people

Study of Inherited Metabolic Diseases:Inherited Metabolic Diseases comprise of a wide spectrum of disorders and may cause serious symptoms and death. The study investigates these disorders in children suspected to have an IMD using a range of new generation genetic and biochemical techniques, including blood, urine and skin biopsies, which will be tested and analysed to give a better understanding of what makes the children ill and therefore hopefully provide better life changing therapies for them. For more information, please contact

Learning disabilities

People with AuTism detained within hospitals: defining the population, understanding aetiology and improving Care patHways (mATCH):The aim of the study is to understand clinical presentations, risk behaviours, treatment needs and responses to treatment of those with Autism Spectrum Disorders who are detained under the Mental Capacity Act, the problems in identifying these differences means that some patients stay in restrictive hospital settings for longer than needed. TEWV are currently taking part in work package 2b, where participants from inpatient hospitals will be asked totake part in standardised assessments and tasks including measures of their traits and executive functioning. For more information, please contact

Forensic mental health

Validation of risk assessments for patients from medium secure services (VoRAMSS):The aim of this study is to test new risk assessment tools that focus on community violence and overcome previous methodological problems. The sample will include patients released from all 38 Medium Secure Services in England and Wales over a 12 month period, who have a diagnosis of Schizophrenia. All patients aged between 18 and 65 discharged from NHS Medium Secure Pathways in a 12 month period will be eligible. For more information please contact

Liaison and Diversion Trial Schemes in England: an evaluation of impact on reconviction, health service utilisation and diversion from the criminal justice system (RAND):The evaluation will examine how the new model of Liaison and Diversion (L&D) is implemented, its impacts on organisations and on people in contact with L&D services, and its costs and benefits. We will conduct interviews with key individuals working within the L&D service, in health/social care and criminal justice services that will be impacted by the L&D service, and individuals using the L&D service. We will also conduct interviews in non-trial sites. We will collect data to compare similar individuals who have and have not been involved with L&D services, allowing us to assess whether L&D services being trialed offer benefits over locally developed services or areas that do not have L&D services.  For more information regarding the trial please contact



Was this information useful? Please let us know by clicking here.